Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 147 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Methamphetamine Disorders Clear all
Completed Phase 2 Interventional

Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

NCT06538285
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Ketamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francicso, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 5, 2026, 9:56 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

NCT04982796
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Psilocybin, Treatment-as-usual
Drug · Behavioral
Lead sponsor
Portland VA Research Foundation, Inc
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Vancouver, Washington
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 5, 2026, 9:56 PM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetics of Naltrexone for Stimulant Abuse

NCT03226223
View directory record Official record
Conditions
Substance Use Disorders, Methamphetamine Abuse
Interventions
Intranasal Methamphetamine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 5, 2026, 9:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Efficacy of Atomoxetine for Methamphetamine Dependence

NCT01557569
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Atomoxetine, placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 5, 2026, 9:56 PM EDT
Completed Phase 1 Interventional

Integrating Interventions for Maternal Substance Abuse

NCT01188434
View directory record Official record
Conditions
Substance Abuse, Child Neglect
Interventions
ITSAN, Services as Usual
Behavioral
Lead sponsor
Oregon Social Learning Center
Other
Eligibility
Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 5, 2026, 9:56 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward

NCT00600145
View directory record Official record
Conditions
Amphetamine Dependence
Interventions
Mirtazapine, Placebo
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Sep 5, 2026, 9:56 PM EDT
Completed Not applicable Interventional

Demonstration of a Digital Care Program for Methamphetamine Use Disorder

NCT05206175
View directory record Official record
Conditions
Methamphetamine Abuse
Interventions
Affect Treatment Program for Methamphetamine Use Disorder
Other
Lead sponsor
Affect Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 5, 2026, 9:56 PM EDT
Completed Not applicable Interventional

Neurocognitive Empowerment for Addiction Treatment (NEAT) in Opioid Use Disorder and Amphetamine Use Disorder

NCT03922646
View directory record Official record
Conditions
Opioid-use Disorder, Amphetamine Use Disorders
Interventions
Neurocognitive Empowerment for Addiction Treatment (NEAT), Active Control
Behavioral
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 5, 2026, 9:56 PM EDT
Completed Not applicable Interventional

Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder

NCT05266716
View directory record Official record
Conditions
Methamphetamine Abuse
Interventions
Affect Methamphetamine Treatment Program
Behavioral
Lead sponsor
Affect Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 5, 2026, 9:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DOX as a Potential Treatment for Methamphetamine Dependence

NCT02785393
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Sugar Pill, Doxazosin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Sep 5, 2026, 9:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants

NCT06316973
View directory record Official record
Conditions
Substance Use Disorders, Methamphetamine Abuse, Methamphetamine Intoxication
Interventions
CS-1103, Sterile Saline
Drug
Lead sponsor
Clear Scientific, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 5, 2026, 9:56 PM EDT
Completed No phase listed Observational

Amphetamine Induced Adult Respiratory Distress Syndrome

NCT05611385
View directory record Official record
Conditions
Burns, Acute Lung Injury, Acute Respiratory Distress Syndrome, Methamphetamine Abuse
Interventions
Difference in development of Acute Lung Injury in Amphetamine positive and negative patients
Other
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 5, 2026, 9:56 PM EDT
Recruiting Phase 2 Interventional

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

NCT05783817
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
3,4-Methyl enedioxy methamphetamine, Methamphetamine, Cognitive Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
Carolyn Rodriguez
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 5, 2026, 9:56 PM EDT
Terminated Phase 1 Interventional

Study of Pomaglumetad and Methamphetamine

NCT03106571
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Pomaglumetad methionil, Placebo, Methamphetamine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Sep 5, 2026, 9:56 PM EDT
Terminated Phase 1 Interventional

Behavioral Therapy Development for Methamphetamine Abuse

NCT00252434
View directory record Official record
Conditions
Depression, Drug Abuse, Sexually Transmitted Diseases
Interventions
Cognitive Behavioral Therapy Development for Methamphetamine Abuse
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years · Male only
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 5, 2026, 9:56 PM EDT
Completed Phase 1 Interventional

Oxytocin HIV Meth Study

NCT02881177
View directory record Official record
Conditions
Amphetamine Use Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 5, 2026, 9:56 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Open-Label Creatine Study for Female Meth Users

NCT02189915
View directory record Official record
Conditions
Depression, Dual Diagnosis, Substance Use
Interventions
Creatine monohydrate
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
13 Years to 55 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 5, 2026, 9:56 PM EDT
Enrolling by invitation Phase 2 Interventional

An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

NCT07693608
View directory record Official record
Conditions
Obesity, Methamphetamine Use Disorder, Cocaine Use Disorder, Stimulant Use Disorders
Interventions
Tirzepatide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 5, 2026, 9:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM

NCT00318409
View directory record Official record
Conditions
Substance Abuse, HIV Infections
Interventions
Bupropion, Placebo
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Sep 5, 2026, 9:56 PM EDT
Recruiting Not applicable Interventional

Deep TMS of Neural Circuits Associated With Stimulant Use Disorder

NCT06578429
View directory record Official record
Conditions
Methamphetamine Use Disorder, Transcranial Magnetic Stimulation
Interventions
Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Active, Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Sham
Device
Lead sponsor
Stanford University
Other
Eligibility
25 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 5, 2026, 9:56 PM EDT
Terminated Phase 2 Interventional Results available

Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

NCT04715230
View directory record Official record
Conditions
Methamphetamine Intoxication (Disorder)
Interventions
IXT-m200, Lorazepam, Haloperidol
Biological · Drug
Lead sponsor
InterveXion Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Little Rock, Arkansas • Albuquerque, New Mexico • Everett, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 5, 2026, 9:56 PM EDT
Not listed Not applicable Interventional

Floatation-REST in Methamphetamine Use Disorder: A Pilot Study

NCT05799209
View directory record Official record
Conditions
Amphetamine-Type Substance Use Disorder
Interventions
Float Pool, Float Chair
Device
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 5, 2026, 9:56 PM EDT
Completed Not applicable Interventional Results available

Pilot TMS for Methamphetamine Use Disorder

NCT04449055
View directory record Official record
Conditions
Stimulant Dependence, Methamphetamine-dependence, Addiction, Drug
Interventions
Transcranial Magnetic Stimulation--DPFC first, MPFC second, Transcranial Magnetic Stimulation--MPFC first, DPFC second
Device
Lead sponsor
Ryan M. Carnahan
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 5, 2026, 9:56 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin for Methamphetamine Use Disorder

NCT07774702
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct)., Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions).
Drug · Behavioral
Lead sponsor
Peter Hendricks
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 5, 2026, 9:56 PM EDT